Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8145700 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1TDP1HTR2ASLC6A4 | |
| SCHEMBL3312647 | 0.95 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1TDP1HTR2ASLC6A4 | |
| SCHEMBL3304900 | 0.90 | HTR2A (0.50) | SMN1; SMN2ALDH1A1TDP1HTR2ASLC6A4 | |
| SCHEMBL31381393 | 0.90 | TSHR (0.52) | SMN1; SMN2ALDH1A1TDP1HTR2ASLC6A4 | |
| SCHEMBL596661 | 0.84 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1TDP1HTR2ASLC6A4 | |
| SCHEMBL597657 | 0.84 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1TDP1HTR2ASLC6A4 | |
| SCHEMBL3305237 | 0.82 | SLC6A4 (0.56) | SMN1; SMN2ALDH1A1HTR2ASLC6A4SLC6A2 | |
| SCHEMBL30976497 | 0.82 | SLC6A4 (0.56) | SMN1; SMN2ALDH1A1HTR2ASLC6A4SLC6A2 | |
| SCHEMBL27985062 | 0.82 | SLC6A4 (0.56) | SMN1; SMN2ALDH1A1HTR2ASLC6A4SLC6A2 | |
| SCHEMBL2181771 | 0.80 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1TDP1PDK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2958181-B1 | NON-AQUEOUS ELECTROLYTIC SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEM CORP (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9653754-B2 | Nonaqueous electrolytes and nonaqueous-electrolyte secondary batteries employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-05-16 | — | — | US | disclosed |
| US-9620814-B2 | — | — | 2017-04-11 | — | — | US | disclosed |
| US-9515348-B2 | Nonaqueous electrolytic solution and nonaqueous-electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20160250219-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-09-01 | — | — | US | disclosed |
| US-9382216-B2 | Substituted morpholines as modulators for the calcium sensing receptor | LUPIN LIMITED (IN) | 2016-07-05 | — | — | US | disclosed |
| US-9231277-B2 | Nonaqueous electrolytes and nonaqueous-electrolyte secondary batteries employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-01-05 | — | — | US | disclosed |
| EP-2958181-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2015-12-23 | — | — | EP | disclosed |
| EP-2535976-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION, AND SECONDARY BATTERY COMPRISING THE SAME | MITSUBISHI CHEM CORP (JP) | 2015-09-02 | — | — | EP | disclosed |
| US-9048508-B2 | Nonaqueous electrolytes and nonaqueous-electrolyte secondary batteries employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-06-02 | — | — | US | disclosed |
| EP-2535976-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-20120308881-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQEUOUS-ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120264010-A1 | NONAQUEOUS ELECTROLYTES AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERIES EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-10-18 | — | — | US | disclosed |
| WO-2012120476-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | LUPIN LIMITED (IN) | 2012-09-13 | — | — | WO | disclosed |
| US-20100099031-A1 | NONAQUEOUS ELECTROLYTES AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERIES EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2166611-A1 | NONAQUEOUS ELECTROLYTE, AND RECHARGEABLE BATTERY WITH THE NONAQUEOUS ELECTROLYTE | Mitsubishi Chemical Corporation (JP) | 2010-03-24 | — | — | EP | disclosed |
| EP-0858452-B1 | THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2002-03-13 | — | — | EP | disclosed |
| US-6140330-A | USEFUL AS PROTEIN KINASE INHIBITOR; FOR TREATMENT OF AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, MULTIPLE SCLEROSIS, PSORIASIS, ETC., VARIOUS ALLERGIC DISEASES SUCH AS CROHN'S DISEASE, ASTHMA | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-10-31 | — | — | US | disclosed |
| EP-0858452-A1 | THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-08-19 | — | — | EP | disclosed |
| WO-1998004536-A1 | THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250219-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | CASR, RYR1, RYR2 | SMN1; SMN2 661/4885ALDH1A1 3779/4885TDP1 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.